Corpus overview


Overview

MeSH Disease

Fever (22)

Cough (16)

Dyspnea (12)

Infections (11)

Hypertension (10)


Human Phenotype

Cough (27)

Fever (22)

Hypertension (10)

Fatigue (9)

Dyspnea (7)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 27
    records per page




    Dynamic Change of COVID-19 Seroprevalence SERO among Asymptomatic TRANS Population in Tokyo during the Second Wave

    Authors: Sawako Hibino; Kazutaka Hayashida; Andrew C Ahn; Yasutaka Hayashida; Julia Bielicki; Tim Roloff; Roland Bingisser; Christian Nickel; Nina Khanna; Sarah Tschudin; Andreas Widmer; Katharina Rentsch; Hans Pargger; Martin Siegemund; Daiana Stolz; Michael Tamm; Stefano Bassetti; Michael Osthoff; Manuel Battegay; Adrian Egli; Hans H Hirsch; Christine Goffinet; Florian Kurth; Martin Witzenrath; Maria Theresa Völker; Sarah Dorothea Müller; Uwe Gerd Liebert; Naveed Ishaque; Lars Kaderali; Leif Erik Sander; Sven Laudi; Christian Drosten; Roland Eils; Christian Conrad; Ulf Landmesser; Irina Lehmann

    doi:10.1101/2020.09.21.20198796 Date: 2020-09-23 Source: medRxiv

    Importance: Fatality rates related to COVID-19 in Japan have been low compared to Western Countries and have decreased despite the absence of lockdown. Serological tests SERO monitored across the course of the second wave can provide insights into the population-level prevalence SERO and dynamic patterns of COVID-19 infection MESHD. Objective: To assess changes in COVID-19 seroprevalence SERO among asymptomatic TRANS employees working in Tokyo during the second wave. Design: We conducted an observational cohort study. Healthy volunteers working for a Japanese company in Tokyo were enrolled from disparate locations to determine seropositivity against COVID19 from May 26 to August 25, 2020. COVID-19 IgM and IgG antibodies SERO were determined by a rapid COVID19 IgM/IgG test kit using fingertip blood SERO. Across the company, tests were performed and acquired weekly. For each participant, serology tests were offered twice, separated by approximately a month, to provide self-reference of test results and to assess for seroconversion and seroreversion. Setting: Workplace setting within a large company. Participants: Healthy volunteers from 1877 employees of a large Japanese company were recruited to the study from 11 disparate locations across Tokyo. Participants having fever HP fever MESHD, cough HP cough MESHD, or shortness of breath MESHD at the time of testing were excluded. Main Outcome(s) and Measure(s): Seropositivity rate (SPR) was calculated by pooled data from each two-weeks window across the cohort. Either IgM or IgG positivity was defined as seropositive. Changes in immunological status against SARS-CoV-2 were determined by comparing results between two tests obtained from the same individual. Results: Six hundred fifteen healthy volunteers (mean + SD 40.8 + 10.0; range 19-69; 45.7 % female TRANS) received at least one test. Seroprevalence SERO increased from 5.8 % to 46.8 % over the course of the summer. The most dramatic increase in SPR occurred in late June and early July, paralleling the rise in daily confirmed cases TRANS within Tokyo, which peaked on August 4. Out of the 350 individuals (mean + SD 42.5 + 10.0; range 19-69; 46.0 % female TRANS) who completed both offered tests, 21.4 % of those individuals who tested seronegative became seropositive and seroreversion was found in 12.2 % of initially seropositive participants. 81.1% of IgM positive cases at first testing became IgM negative in approximately one month. Conclusions and Relevance: COVID-19 infection MESHD may have spread widely across the general population of Tokyo despite the very low fatality rate. Given the temporal correlation between the rise in seropositivity and the decrease in reported COVID-19 cases that occurred without a shut-down, herd immunity may be implicated. Sequential testing for serological SERO response against COVID-19 is useful for understanding the dynamics of COVID-19 infection at the population-level.

    Features of patients that died for COVID-19 in a Hospital in the south of Mexico: A observational cohort study

    Authors: Jesus Arturo Ruiz-Quinonez Sr.; Crystell Guzman-Priego Sr.; German Alberto Nolasco-Rosales Sr.; Carlos Alfonso Tovilla-Zarate; Oscar Israel Flores-Barrientos; Victor Narvaez-Osorio; Guadalupe del Carmen Baeza-Flores; Thelma Beatriz Gonzalez-Castro; Carlos Ramon Lopez-Brito; Carlos Alberto Denis-Garcia; Agustin Perez-Garcia; Isela Esther Juarez-Rojop; Zhen Cui; Qing Ye; Geng Chen; Kui-Kui Lu; Yin Chen; Yu-Tao Chen; Hong-Xing Pan; Bao-Li Zhu; Cheng-Feng Qin; Xiangxi Wang; Feng-Cai Zhu

    doi:10.1101/2020.09.21.20199117 Date: 2020-09-23 Source: medRxiv

    Background: Due to the wide spread of SARS-CoV2 around the world, the risk of death MESHD in individuals with metabolic comorbidities has dangerously increased. Mexico has a high number of infected individuals and deaths by COVID-19, as well as an important burden of metabolic diseases MESHD. However, reports about features of Mexican individuals with COVID-19 are scarce. The aim of this study was to evaluate demographic features, clinical characteristics, and the pharmacological treatment of individuals who died by COVID-19 in the south of Mexico. Methods: We performed an observational study including 185 deceased individuals with confirmed diagnosis of COVID-19. Data were retrieved from medical records. Categorical data was expressed as proportions (%) and numerical data were expressed as mean, standard deviation. Comorbidities and overlapping symptoms where plotted as Venn diagrams. Drug clusters were plotted as dendrograms. Results: The mean age TRANS was 59.53 years. There was a male TRANS predominance (60.1%). The mean hospital stay was 4.75 days. The most frequent symptoms were dyspnea HP dyspnea MESHD (88.77%), fever HP fever MESHD (71.42%) and dry cough MESHD cough HP (64.28%). Present comorbidities were diabetes MESHD (60.63%), hypertension HP hypertension MESHD (59.57%) and obesity HP obesity MESHD (43.61%). The main drugs used were azithromycin (60.6%), hydroxychloroquine (53.0%) and oseltamivir (27.3%). Conclusions: Mexican individuals who died of COVID-19 had shorter hospital stays, higher frequency of shortness of breath MESHD, and higher prevalence SERO of diabetes MESHD compared with individuals from other countries. Also, there was a high frequency of off-label use of drugs for their treatment.

    Ruling In and Ruling Out COVID-19: Computing SARS-CoV-2 Infection Risk TRANS Infection Risk TRANS From Symptoms, Imaging and Test Data.

    Authors: Chistopher D'Ambrosia; Henrik Christensen; Eliah Aronoff-Spencer

    doi:10.1101/2020.09.18.20197582 Date: 2020-09-22 Source: medRxiv

    Background: Assigning meaningful probabilities of SARS CoV2 infection risk TRANS infection risk TRANS presents a diagnostic challenge across the continuum of care. Methods: We integrated patient symptom and test data using machine learning and Bayesian inference to quantify individual patient risk of SARS CoV 2 infection MESHD. We trained models with 100,000 simulated patient profiles based on thirteen symptoms, estimated local prevalence SERO, imaging, and molecular diagnostic performance SERO from published reports. We tested these models with consecutive patients who presented with a COVID 19 compatible illness at the University of California San Diego Medical Center over 14 days starting in March 2020. Results: We included 55 consecutive patients with fever HP fever MESHD (78%) or cough HP cough MESHD (77%) presenting for ambulatory (n=11) or hospital care (n=44). 51% (n=28) were female TRANS, 49% were age TRANS <60. Common comorbidities included diabetes MESHD (22%), hypertension HP hypertension MESHD (27%), cancer MESHD (16%) and cardiovascular disease MESHD (13%). 69% of these (n=38) were RT-PCR confirmed positive for SARS CoV2 infection, 11 had repeated negative nucleic acid testing and an alternate diagnosis. Bayesian inference network, distance metric learning, and ensemble models discriminated between patients with SARS CoV2 infection MESHD and alternate diagnoses with sensitivities SERO of 81.6 to 84.2%, specificities of 58.8 to 70.6%, and accuracies of 61.4 to 71.8%. After integrating imaging and laboratory test statistics with the predictions of the Bayesian inference network, changes in diagnostic uncertainty at each step in the simulated clinical evaluation process were highly sensitive to location, symptom, and diagnostic test choices. Conclusions: Decision support models that incorporate symptoms and available test results can help providers diagnose SARS CoV2 infection MESHD in real world settings.

    Epidemiology and clinical outcome of COVID-19: A multi-centre cross sectional study from Bangladesh

    Authors: Adnan Mannan; H.M. Hamidullah Mehedi; Naim Hasan Chy; Md. Omar Qayum; Farhana Akter; Abdur Rob; Prasun Biswas; Sanjida Hossain; Mustak Ibn Ayub; Nardin Rezk; Annarita Giliberti; Alessandra Renieri; Yiheng Chen; Sirui Zhou; Vincenzo Forgetta; J Brent Richards

    doi:10.1101/2020.09.09.20191114 Date: 2020-09-10 Source: medRxiv

    Objectives: To investigate SARS-CoV-2 associated epidemiology and clinical outcomes in Bangladesh to understand the course of COVID-19 pandemic and suggest prevention measures. Methods: A cross-sectional retrospective study was conducted among 1,021 RT-PCR confirmed but recovered COVID-19 cases from six participating hospitals in Bangladesh. Results: Of the total sample, 111 (10.9%) cases were asymptomatic TRANS while the number of symptomatic cases were 910 (89.1%). Higher prevalence SERO of COVID-19 persisted in the male TRANS population (75%) and for the 31-40 age group TRANS. More than 85% of the samples reported BCG vaccination mark. Common symptoms observed in our study samples were fever HP fever MESHD (72.4%), cough HP (55.9%), loss of taste MESHD (40.7%) and body ache MESHD (40%); whereas for the biochemical parameters, Neutrophil (46.4%), D-dimer (46.1%), Ferritin (37.9%) and SGPT (36.8%) levels were found elevated. Post-COVID complications including pain HP pain MESHD (31.8%), loss of concentration (24.4%) and anxiety HP anxiety MESHD or depression (23.1%) were found significantly prevalent. Conclusion: Our study has shown that adult TRANS males TRANS aged TRANS between 31-40 in Bangladesh are more vulnerable to being infected with COVID-19. With an indication for the rising trend of the asymptomatic TRANS cases, deployment of interventions to curb further community spread is necessary to avoid the grave outcomes of COVID-19 in Bangladesh.

    Gastrointestinal symptoms in coronavirus disease MESHD 2019: a cross-sectional study in Wuhan, China

    Authors: Yong Zhang; Zuneng Lu; Bo Wang; Jinxing Chang; Yonggang Ma

    doi:10.21203/rs.3.rs-69884/v1 Date: 2020-09-01 Source: ResearchSquare

    Background To investigate the clinical symptoms of coronavirus disease MESHD 2019 (COVID-19), particularly the prevalence SERO, time of symptom onset TRANS, and duration of gastrointestinal ( GI MESHD) symptoms.Methods This was a cross-sectional study using paper questionnaires. COVID-19 patients in a temporary hospital in Wuhan voluntarily completed surveys collecting data on COVID-19 symptoms and investigation results.Results A total of 212 adults TRANS were enrolled in this study, of whom 127 (59.9%) were female TRANS, mean age TRANS was 48.50 ± 13.15 years. Concerning symptoms, 78.8% (167/212) had fever HP fever MESHD, and 66% (140/212) had cough HP. Diarrhoea MESHD occurred in 43.8% (93/212) of patients. Nausea and vomiting HP Nausea and vomiting MESHD vomiting MESHD were also common (20.7%). Fever HP Fever MESHD and cough HP cough MESHD were frequently the initial symptoms of COVID-19, and they lasted for 5.00 [interquartile range (IQR): 3.00–10.00] days and 10.00 (IQR: 5.00–24.00) days, respectively. Most patients developed nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD 2.00 (IQR: 0–9.00) days and diarrhoea MESHD 5.00 (IQR: 0.25–11.00) days after the onset of initial symptoms, respectively. There was a median duration of 4.00 (IQR: 2.00–8.75) days with diarrhoea MESHD, and 6.00 (IQR: 4.00–10.00) days with nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD. The patients with diarrhoea MESHD were younger [45.85 ± 13.28 years vs 50.61 ± 12.82 years, P = 0.009] and were more likely to have an abnormal chest CT (95.7% vs 82.4%, P = 0.001) than those without diarrhoea MESHD.Conclusions In our cohort of patients, GI symptoms MESHD were common in COVID-19, occurred mostly during the middle stage of the disease, and lasted for a short duration. GI MESHD symptoms may not be associated with COVID-19 related treatment.

    The Prevalence SERO and Clinical Significance of Presymptomatic COVID-19 Patients: How We Can be One Step Ahead in Mitigating a Deadly Pandemic

    Authors: Juen Kiem Tan; Dalleen Leong; Hemalatha Munusamy; Nor Hazwani Zenol Ariffin; Najma Kori; Rozita Hod; Petrick Periyasamy

    doi:10.21203/rs.3.rs-60558/v1 Date: 2020-08-16 Source: ResearchSquare

    Presymptomatic COVID-19 patients have been identified as a major stumbling block in efforts to break the chain of transmission TRANS. Studies on temporal dynamics of its shedding suggests it peaks 1-2 days prior to any symptom onset TRANS. Therefore, a large proportion of patients are actively spreading the disease TRANS unknowingly whilst undetected. However, lengthy lockdowns and isolation leads to a host of socioeconomic issues and are impractical. Conversely, there exists no study describing this group and their clinical significance despite their key role in disease transmission TRANS. As a result, we devised a study to look at the prevalence SERO of presymptomatic patients with COVID-19 and subsequently, identify early indicators of infection MESHD through demographic information, biochemical and radiological abnormalities which would allow early diagnosis and isolation. In addition, we will look into the clinical significance of this group and their outcome; if it differs from asymptomatic TRANS or symptomatic patients. Our analysis shows a higher proportion of presymptomatic patients with atypical symptoms like chest pain HP chest pain MESHD while symptomatic patients commonly present with respiratory symptoms like cough HP cough MESHD and shortness of breath MESHD. Besides that, there were more females TRANS presenting as presymptomatic patients and receiving treatment compared to males TRANS and this was found to be statistically significant. Otherwise, we were not able to identify other statistically significant markers suggesting a patient is presymptomatic. As we have little means of identifying these silent spreaders, it highlights further the importance of general measures implemented to stop COVID-19 transmission TRANS like social distancing, face mask, and widespread testing.

    Estimates of the rate of infection MESHD and asymptomatic TRANS COVID-19 disease in a population sample from SE England

    Authors: Philippa M Wells; Katie M Doores; Simon Couvreur; Rocio Martin Martinez; Jeffrey Seow; Carl Graham; Sam Acors; Neophytos Kouphou; Stuart Neil; Richard Tedder; Pedro Matos; Kate Poulton; Maria Jose Lista; Ruth Dickenson; Helin Sertkaya; Thomas Maguire; Edward Scourfield; Ruth Bowyer; Deborah Hart; Aoife O'Byrne; Kathryn Steele; Oliver Hemmings; Carolina Rosadas; Myra McClure; Joan Capedevila-Pujol; Jonathan wolf; Sebastien Ourseilin; Matthew Brown; Michael Malim; Timothy Spector; Claire Steves

    doi:10.1101/2020.07.29.20162701 Date: 2020-07-30 Source: medRxiv

    Background: Understanding of the true asymptomatic TRANS rate of infection of SARS-CoV-2 MESHD is currently limited, as is understanding of the population-based seroprevalence SERO after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. Methods: We undertook enzyme linked immunosorbent assay SERO characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged TRANS 19-86 (median age TRANS 48; 85% female TRANS). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. Findings: We demonstrated a seroprevalence SERO of 12% (51participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic TRANS, and 16 (27%) were asymptomatic TRANS for core COVID-19 symptoms: fever HP fever MESHD, cough HP cough MESHD or anosmia HP anosmia MESHD. Specificity of anosmia HP anosmia MESHD for seropositivity was 95%, compared to 88% for fever HP fever MESHD cough HP and anosmia HP anosmia MESHD combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. Interpretation: Seroprevalence SERO amongst adults TRANS from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic TRANS throughout the study. Anosmia HP demonstrated the highest symptom specificity for SARS-CoV-2 antibody SERO response. Funding: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC

    Older adults TRANS hospitalized with Covid-19: Clinical characteristics and early outcomes from a single center in Istanbul, Turkey 

    Authors: Alpay Medetalibeyoğlu; Naci Senkal; Murat Kose; Yunus Catma; Emine Bilge Caparali; Mustafa Erelel; Mustafa Oral Oncul; Gulistan Bahat; Tufan Tukek

    doi:10.21203/rs.3.rs-47728/v1 Date: 2020-07-22 Source: ResearchSquare

    Objective: Older adults TRANS have been continuously reported to be at higher risk for adverse outcomes of Covid-19. We aimed to describe clinical characteristics and early outcomes of the older Covid-19 patients hospitalized in our center comparatively with the younger patients, and also to analyze the triage factors that were related to the in-hospital mortality of older adults TRANS.Design: Retrospective; observational studySetting: Istanbul Faculty of Medicine hospital, TurkeyParticipants: 362 hospitalized patients with laboratory-confirmed Covid-19 from March 11 to May 11, 2020.Measurements: The demographic information; associated comorbidities; presenting clinical, laboratory, radiological characteristics on admission and outcomes from the electronic medical records were analyzed comparatively between the younger (<65 years) and older (≥65 years) adults TRANS. Factors associated with in-hospital mortality of the older adults TRANS were analyzed by multivariate regression analyses.Results: The median age TRANS was 56 years (interquartile range [IQR], 46-67), and 224 (61.9%) were male TRANS. There were 104 (28.7%) patients ≥65 years of age TRANS. More than half of the patients (58%) had one or more chronic comorbidity. The three most common presenting symptoms in the older patients were fatigue HP atigue/ MESHD myalgia HP yalgia MESHD(89.4%), d ry cough MESHD cough HP (72.1%), and fever HP ever MESHD(63.5%). Cough HP and fever HP ever MESHDwere significantly less prevalent in older adults TRANS compared to younger patients (p=0.001 and 0.008, respectively). Clinically severe pneumonia HP neumonia MESHDwas present in 31.5% of the study population being more common in older adults TRANS (49% vs. 24.4%) (p<0.001). The laboratory parameters that were significantly different between the older and younger adults TRANS were as follows: the older patients had significantly higher CRP, D-dimer, TnT, pro-BNP, procalcitonin levels, higher prevalence SERO of lymphopenia HP ymphopenia, MESHD neutrophilia HP, increased creatinine, and lower hemoglobin, ALT, albumin level (p<0.05). In the radiological evaluation, more than half of the patients (54.6%) had moderate-severe pneumonia HP neumonia, MESHD which was more prevalent in older patients (66% vs. 50%) (p=0.006). The adverse outcomes were significantly more prevalent in older adults TRANS compared to the younger patients (ICU admission, 28.8% vs. 8.9%; mortality, 23.1% vs. 4.3%, p<0.001).  Among the triage evaluation parameters, the only factor associated with higher mortality was the presence of clinically severe pneumonia HP neumonia MESHDon admission (Odds Ratio=12.3, 95% confidence interval=2.7-55.5, p=0.001).Conclusion: Older patients presented with more prevalent chronic comorbidities, less prevalent symptomatology but more severe respiratory signs and l aboratory abnormalities MESHDthan the younger patients. Among the triage assessment factors, the clinical evaluation of pulmonary involvement came in front to help clinicians to stratify the patients for mortality risk.

    Clinical characteristics and Mortality risk factors among COVID-19 patients in Qom–Iran; The results of a Retrospective Cohort study

    Authors: Ahmad Hormati; SeyedYaser Foroghi Ghomi; masoudreza sohrabi; Ali Gholami; Saeede Jafari; Amir Jabbari; Reza AminNejad; Javad Khodadadi; Mansoureh shakeri; Alireza ShahHamzeh; Mahbobeh Afifian; Zohre Azad; Sajjad Ahmadpour; MohammadHadi Karbalai; MohammadReza Babaei; Parisa Karimzadeh; SeyedKamal Esshagh Hosseini

    doi:10.21203/rs.3.rs-42497/v1 Date: 2020-07-13 Source: ResearchSquare

    Background & AimCoronavirus 2019 (COVID-19) outbreak in the Middle East was initially reported in Qom-Iran. Clinical and epidemiologic and mortality risk factors details have not been already fully explained.MethodIn a retrospective study, the hospitalized adult TRANS patients with laboratory diagnosed COVID-19 between February 25 to March 20, 2020 were enrolled. A checklist including demographic, clinical, laboratorial, imaging, and treatment data was completed for each of the participant. The data were extracted from electronic medical records. In case of lack of information, a member of the research team contacted them via phone. All the dead patients and the first one hundred survived patients with these criteria were enrolled in the study. Outcome defined as death MESHD or discharge of patients.ResultsOf admitted patients, 200 patients who had been discharged or died were involved in this study. The majority of them were male TRANS (56%). The mean age TRANS of all patients was 62.63 ± 14.9. Co-morbidity was reported in 124 (62%) patients in which hypertension HP hypertension MESHD was the most common. The most frequent clinical presentations were dyspnea HP dyspnea MESHD in 169 (84.5%), cough HP cough MESHD in 150 (75%), and fatigue HP fatigue MESHD/weakness in 123 (61.5%) patients. The main complications were respiratory failure HP respiratory failure MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome with prevalence SERO of 143 (71.5%) and 105 (52.5%), accordingly. Multiple logistic models showed that decline of hemoglobin level (OR = 10.09), neutrophilia HP (OR = 3.48), high blood SERO urea nitrogen (OR = 4.29,), SpO2 ≤ 90% (OR = 3.38), and presence of patchy consolidation (OR = 6.81) were associated with poor outcome.ConclusionCOVID-19 disease has multiple aspects. CT scan findings, complete blood SERO count with differential, high blood SERO urea nitrogen and SpO2 are related to mortality. Hence needs to pay serious attention during admitting and surveillance, particularly among elderly TRANS patients and who with preexisting morbidities.

    A population-based study of the prevalence SERO of COVID-19 infection MESHD in Espirito Santo, Brazil: methodology and results of the first stage

    Authors: Cristiana Costa Gomes; Crispim Cerutti Jr.; Eliana Zandonade; Ethel Leonor Noia Maciel; Filomena Euridice Carvalho de Alencar; Gilton Luiz Almada; Orlei Amaral Cardoso; Pablo Medeiros Jabor; Raphael Lubiana Zanotti; Tania Queiroz Reuter; Vera Lucia Gomes de Andrade; Whisllay Maciel Bastos; Nesio Fernandes de Medeiros Jr.

    doi:10.1101/2020.06.13.20130559 Date: 2020-06-16 Source: medRxiv

    BACKGROUND: COVID-19 is affecting almost the entire world, causing more than four hundred thousand deaths and undermining the health care systems, as much as the economy, of the afflicted countries. The strategies for prevention depend on largely lacking information, as infection MESHD prevalence SERO and virus pathogenicity. This study aimed to determine the prevalence SERO, the pathogenicity, and the speed of infection MESHD spreading in a large population in Brazil. MATERIALS AND METHODS: This is a serial cross-sectional study designed on a population basis and structured over houses as the sampling units. The sampling consisted of four visits at 15 days intervals in randomly selected census-designated sectors of the State major municipalities (reference municipalities) and two visits at 30 days intervals in smaller municipalities of the same regions of those of reference. At each visit, the investigators sampled houses and sampled one individual in each house for data collection. After the informed consent, the investigators performed a rapid antibody SERO detection test (Celer Technology, Inc) and applied a questionnaire containing clinical and demographic questions. RESULTS: From May 13th to 15th, the investigators performed 6,393 rapid tests SERO in 4,612 individuals of the reference municipalities, 1,163 individuals of the smaller municipalities, and 166 contacts of the positive individuals. Ninety-seven dwellers were positive in the reference municipalities, giving a prevalence SERO of 2.1% (CI 95%: 1.67-2.52%). In the smaller municipalities, the figure was 0.26% (CI 95%: 0.05%-0.75%) (three positives). There was an association of the positive result with female TRANS sex (p = 0.013) and houses with five dwellers or more (p = 0.003). Seventy-eight positive individuals reported symptoms in the previous 15 days (80.4%), being anosmia HP anosmia MESHD (45.4%), cough HP (40.2%), and myalgia HP myalgia MESHD (38.1%) the more frequent. About one-third of them reported fever HP fever MESHD (28.9%). CONCLUSIONS: The results reveal a still small prevalence SERO of infection MESHD in the study area, despite the significant number of sick people overloading the health system. The figures indicate an important underreporting in the area and a frequency that still can grow, making necessary public health actions for the containment of the transmission TRANS.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.